These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 30841025

  • 1. LncRNA MALAT1 Depressed Chemo-Sensitivity of NSCLC Cells through Directly Functioning on miR-197-3p/p120 Catenin Axis.
    Yang T, Li H, Chen T, Ren H, Shi P, Chen M.
    Mol Cells; 2019 Mar 31; 42(3):270-283. PubMed ID: 30841025
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.
    Liu J, Tian W, Zhang W, Jia Y, Yang X, Wang Y, Zhang J.
    Biomed Pharmacother; 2019 Jun 31; 114():108847. PubMed ID: 30970294
    [Abstract] [Full Text] [Related]

  • 3. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ, Wu YP, Wang D, Zhou ZH, Xue SB, Zhang DY, Wei YG, Liu W.
    Med Sci Monit; 2019 Oct 29; 25():8095-8104. PubMed ID: 31659146
    [Abstract] [Full Text] [Related]

  • 4. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q, Xing S, Peng A, Yu Z.
    Biosci Rep; 2020 Jan 31; 40(1):. PubMed ID: 31894841
    [Abstract] [Full Text] [Related]

  • 5. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2019 Dec 09; 12(1):135. PubMed ID: 31818312
    [Abstract] [Full Text] [Related]

  • 6. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
    Huang J, Lin C, Dong H, Piao Z, Jin C, Han H, Jin D.
    Cancer Chemother Pharmacol; 2020 Nov 09; 86(5):663-672. PubMed ID: 33030583
    [Abstract] [Full Text] [Related]

  • 7. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L, Xu J, Zhao F, Dai X, Tao J, Pan J, Shi A, Shen Z, Su C, Zhang Y.
    Eur J Pharmacol; 2021 May 15; 899():174054. PubMed ID: 33771522
    [Abstract] [Full Text] [Related]

  • 8. LncRNA MALAT1 promotes migration and invasion of non-small-cell lung cancer by targeting miR-206 and activating Akt/mTOR signaling.
    Tang Y, Xiao G, Chen Y, Deng Y.
    Anticancer Drugs; 2018 Sep 15; 29(8):725-735. PubMed ID: 29916897
    [Abstract] [Full Text] [Related]

  • 9. Long Noncoding RNA SNHG6 Promotes Proliferation and Inhibits Apoptosis in Non-small Cell Lung Cancer Cells by Regulating miR-490-3p/RSF1 Axis.
    Dong Z, Liu H, Zhao G.
    Cancer Biother Radiopharm; 2020 Jun 15; 35(5):351-361. PubMed ID: 32202941
    [Abstract] [Full Text] [Related]

  • 10. LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis.
    Wang D, Zhang S, Zhao M, Chen F.
    Cancer Med; 2020 Dec 15; 9(23):9138-9149. PubMed ID: 33146951
    [Abstract] [Full Text] [Related]

  • 11. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.
    Tang Q, Zhou Q, Li J, Yang X, Wang R, Wang X, Xu M, Han L, Wu W, Wang S.
    Carcinogenesis; 2023 Aug 18; 44(6):497-510. PubMed ID: 37144780
    [Abstract] [Full Text] [Related]

  • 12. Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma.
    Wang Z, Chang X, Zhu G, Gao X, Chang L.
    Cell Cycle; 2020 Aug 18; 19(16):2054-2062. PubMed ID: 32663095
    [Abstract] [Full Text] [Related]

  • 13. LncRNA H19 interacted with miR-130a-3p and miR-17-5p to modify radio-resistance and chemo-sensitivity of cardiac carcinoma cells.
    Jia J, Zhang X, Zhan D, Li J, Li Z, Li H, Qian J.
    Cancer Med; 2019 Apr 18; 8(4):1604-1618. PubMed ID: 30843379
    [Abstract] [Full Text] [Related]

  • 14. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S, Wang K, Huang X, Zhao Z, Zhao Z.
    Int J Immunopathol Pharmacol; 2019 Apr 18; 33():2058738419859699. PubMed ID: 31240979
    [Abstract] [Full Text] [Related]

  • 15. Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway.
    Cui Y, Zhang F, Zhu C, Geng L, Tian T, Liu H.
    Oncotarget; 2017 Mar 14; 8(11):17785-17794. PubMed ID: 28147312
    [Abstract] [Full Text] [Related]

  • 16. circ_0007385 served as competing endogenous RNA for miR-519d-3p to suppress malignant behaviors and cisplatin resistance of non-small cell lung cancer cells.
    Ye Y, Zhao L, Li Q, Xi C, Li Y, Li Z.
    Thorac Cancer; 2020 Aug 14; 11(8):2196-2208. PubMed ID: 32602212
    [Abstract] [Full Text] [Related]

  • 17. The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC.
    Li X, Zhang X, Yang C, Cui S, Shen Q, Xu S.
    Cell Cycle; 2018 Aug 14; 17(14):1772-1783. PubMed ID: 30010468
    [Abstract] [Full Text] [Related]

  • 18. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
    Li Q, Wang Y, He J.
    J Clin Lab Anal; 2021 Jul 14; 35(7):e23853. PubMed ID: 34057242
    [Abstract] [Full Text] [Related]

  • 19. MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
    Chen W, Tan X, Yang Q, Fang Z, Xu Y.
    Cell Signal; 2022 Jun 14; 94():110326. PubMed ID: 35367362
    [Abstract] [Full Text] [Related]

  • 20. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis.
    Li S, Mei Z, Hu HB, Zhang X.
    J Cell Physiol; 2018 Sep 14; 233(9):6679-6688. PubMed ID: 29215698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.